摘要
目的：观察喹硫平和氟哌啶醇治疗老年痴呆精神行为症状的疗效和安全性。方法：采用随机对照研究,喹硫平组28例,剂量(130±s 60)mg·d^(-1),25～400mg·d^(-1),氟哌啶醇组23例,剂量(4．8±1．4)mg·d^(-1),2～20mg·d^(-1),疗程12wk,治疗前后采用痴呆病理分析评定量表(BEHAVE-AD)和治疗时出现的症状量表(TESS)评定疗效和不良反应。结果：2组病人治疗后BEHAVE-AD评分显著下降(P＜0．01),2组病人之间治疗前后BEHANE-AD的减分值无显著差异(P＞0．05),氟哌啶醇组44%有锥体外系反应,明显高于喹硫平组的7%,有显著差异(P＜0．05)。结论：喹硫平和氟哌啶醇治疗老年痴呆精神行为症状疗效确切,喹硫平不良反应少。
AIM： To assess the efficacy and safety of quetiapine and haloperidol in the treatment of behav- ioral and psychological symptoms of dementia （BPSD） . METHODS： A randomized comparative study was carried out for 28 patients of quetiapine group which were treated with quetiapine （130 ± s 60） mg.d^-1, 25 - 400 mg. d^-1, individually： and 23 patients of haloperidol group receivid haloperidol （4.8 × 1.4） mg.d^-1, 2 - 20 mg.d^-1, individually; with a course of 12 wk. BEHAVE-AD was used for the pathogenesis analysis of denmentia before and after treatment. TESS was taken for the evaluation of the efficacy and adverse reactions during treatment. RESULTS： After 12 wk treatment, the scores of BEHAVE-AD of patients in both groups were significantly reduced （P 〈 0.01） but no significant difference between them （P 〉 0.05）. The incidence of EPS was 7 % in quetiapine group, which was significantly lower than 44 % in haloperidol group （P 〈 0.05）. CONCLUSION： Quetiapine and haloperidol show good efficacy for treating BPSD. Quetiapine is better with less adverse reaction.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2006年第9期706-708,共3页
Chinese Journal of New Drugs and Clinical Remedies
关键词
痴呆
精神障碍
症状行为
喹硫平
氟哌啶醇
dementia： mental disorders： behavioral symptoms： quetiapine
haloperidol
